

Industry news with an exclusive interview by from Aerie Pharmaceuticals

SMI's Ophthalmic Drugs 2018

LONDON, UNITED KINGDOM, August 2, 2018 /EINPresswire.com/ -- SMI are delighted to have interviewed Mitchell de Long, Vice President, Chemistry, Aerie Pharmaceuticals regarding his thoughts and experiences within the ophthalmology space.

Mitchell A. (Mitch) deLong holds the position of Vice President, Chemistry at Aerie Pharmaceuticals as well as Adjunct Professor of Chemistry at Duke University. Since Mitch helped to found Aerie as a Duke University spinout in 2005, Aerie has filed 5 INDs and 2 NDAs, with its first FDA approval coming in 2017. Mitch is lead inventor on over 50 issued US patents, about half of those at Aerie, and has over 100 publications, posters and presentations. Mitch earned his PhD in Synthetic Organic and Medicinal Chemistry at Stanford University, and has two other marketed [drugs](#) to his credit.

Interview Snapshot:

"New techniques, new ideas and newfound funding sources are revolutionizing the field. Ideas that once were dismissed out-of-hand as farfetched, have been given new life. Delivery of drugs to the retina continues to be the biggest challenge in our field, along with compliance issues..."

Aerie Pharmaceuticals May Revolutionize Glaucoma Treatment

The company's establishing itself as a leader in this growing, multibillion-dollar industry

Aerie Pharmaceuticals announced on Monday that the Food and Drug Administration (FDA) has accepted for review its application for approval of Roclatan, a combination drug consisting of the company's recently approved glaucoma drug, Rhopressa, and the commonly prescribed glaucoma drug latanoprost. If the FDA OKs Roclatan, Aerie Pharmaceuticals' drugs could become standard care in glaucoma patients.*

To hear more about the new drug and latest developments within Aerie Pharmaceuticals, register your place for [Ophthalmic](#) Drugs this November, and hear from the Vice President himself who will be chairing and exploring the advancements in the treatment of glaucoma in his Keynote address: 'The discovery and SAR of netarsudil, the first FDA-approved ROCK inhibitor for the treatment of glaucoma.'



For those looking to attend, there is currently a £200 early-bird saving, ending September 28th:
www.opthalmicdrugs.com/ein

SMi Presents the 2nd annual:
Ophthalmic Drugs 2018
Date: 26th – 27th November 2018
Workshops: 28th November 2018
Location: Copthorne Tara Hotel, London UK
Website: www.opthalmicdrugs.com/ein

Sponsors: Experimentica | Nemera

Source: <https://bit.ly/2mPlgt8>

Follow 'SMi Pharma' on LinkedIn for latest pharmaceutical industry updates.

---end---

Contact Information:

For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Pav Solanki
SMi Group
2078276048
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.
© 1995-2018 IPD Group, Inc. All Right Reserved.